argenx - VYVGART® Hytrulo set for CIDP launch on June 21
*This morning, argx announced FDA acceptance of its CIDP application with priority review voucher (PRV). PDUFA date is set on June 21.*No impact on our estimates as we already modelled approval for this indication around mid this year (likelihood 85%) based on argx's previous guidance indicating its intention to file with PRV. *We do not expect markets to react strongly to this news and look primarily forward to the Ph2 readout in Sjögren's disorder and post-Covid POTS in H1 (currently upside in our model but back-of-the-envelope indicates blockbuster sales potential). Buy reiterated.Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.